Tirzepatide (Mounjaro, Zepbound) and vitamin D — no direct pharmacokinetic interaction but monitoring of vitamin D status is recommended for long-term GLP-1/GIP therapy.
Mounjaro (tirzepatide inj.)Zepbound (tirzepatide inj.)+Vitamin D
🔵
Monitor
Tirzepatide + Vitamin D
No direct interaction. Tirzepatide patients are at elevated risk of vitamin D insufficiency due to reduced caloric intake. Vitamin D monitoring and supplementation at appropriate doses is generally recommended for long-term GLP-1/GIP therapy.
What This Means
In Plain Language
Tirzepatide and vitamin D do not interact pharmacokinetically. However, tirzepatide significantly reduces appetite and food intake, decreasing dietary vitamin D over time. Additionally, tirzepatide's effects on fat absorption may reduce absorption of fat-soluble vitamins including vitamin D. Periodic monitoring of 25-hydroxyvitamin D levels is appropriate for patients on long-term tirzepatide.
Clinical Considerations
Key Risks & Factors
Insufficiency risk with prolonged use: Reduced caloric intake and potential fat absorption changes increase vitamin D insufficiency risk on long-term GLP-1/GIP therapy.
No pharmacokinetic interaction: Vitamin D supplementation does not alter tirzepatide's efficacy or blood levels.
Standard doses are safe: Vitamin D supplementation at 1,000–2,000 IU/day is safe alongside tirzepatide for most adults. Take with a fat-containing meal for optimal absorption.
Conservative Safety Assessment
Vitamin D supplementation at standard doses is compatible with tirzepatide. Monitoring vitamin D status periodically during long-term tirzepatide therapy is prudent clinical practice. This 'Monitor' rating reflects a monitoring recommendation, not a safety concern. Reviewed and audited by Sanford A. Orloff, RPh (ret).
Enter all your medications, supplements, and lifestyle substances to see a complete pharmacist-reviewed interaction report — free, no account required.
Pharmacist-reviewed · FDA & NIH sources only · Always free
👨⚕️
Sanford A. Orloff, RPh (ret)
Registered Pharmacist · 40+ Years Clinical Experience · NPI 1518289974
Every interaction profile on InteractSafe is reviewed for editorial accuracy by a retired pharmacist with over 40 years of clinical experience in medication therapy management, patient counseling, and pharmaceutical care.
Yes — vitamin D at standard doses is safe alongside tirzepatide. There is no direct pharmacokinetic interaction. Vitamin D monitoring is actually recommended for long-term GLP-1/GIP patients due to reduced dietary intake from appetite suppression.
Many physicians recommend vitamin D monitoring and supplementation for patients on long-term GLP-1 medications. Ask your physician to check your 25-OH vitamin D level and recommend an appropriate supplemental dose based on your results.
This profile is for educational purposes only. Reviewed for editorial accuracy by Sanford A. Orloff, RPh (ret).
It is NOT medical advice and does not replace consultation with a licensed physician or pharmacist.
Never change your medication routine based on this information alone.
Read Full Safety Terms →